International Stem Cell Corp. (ISCO)
International Stem Cell Corp. is a California-based biotech company developing novel stem cell-based therapies based on the company’s core technology, parthenogenesis. Utilizing this technology, ISCO has produced pluripotent human stem cells from unfertilized human eggs to create the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals, regardless of gender, age or racial background with minimal immune rejection after transplantation.
For now, ISCO scientists are focused on applying its technology to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver, and the eye, where cell therapy has been clinically proven but is limited due to adequate availability of safe human cells. Upon clinical validation of the technology, there are an essentially unlimited number of potential applications. ISCO's scientists are also making significant advances in human-induced pluripotent stem cells (iPS) derivation with a novel protein-based reprogramming method that is a safer and more efficient alternative to cell reprogramming. The company is currently working toward shortening the cell reprogramming step to as little as one week, as compared to the traditional six-week time frame.
ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (LCT) (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (LSC) (www.lifelineskincare.com).
Most recent sales figures (Q3 2013) were $1.7 million, up 41% from $1.2 million in Q3 2012. Sales for LCT were $860,000, up 30% year-over-year, while LSC revenues increased to $810,000, up 54% over the corresponding period in 2012. The company also decreased its loss from operations by 18 percent to $1.7 million, compared to a loss of $2.1 million in the same period in 2012.
Kallo, Inc. (KALO)
Kallo, Inc. leverages a suite of technologies to improve the quality and efficiency of care in the $6.3 trillion global healthcare industry. Offering centralized, congruent solutions that attend healthcare and business issues, the company addresses the needs of hospitals, ministries of health, physicians, and other healthcare organizations.
As a result of an expanding and aging population, coupled with an increasing number of people suffering from chronic diseases and lifestyle related conditions, healthcare expenditures continue to grow. Kallo is focused on introducing new healthcare technology that helps contain costs, enable better methods to monitor/treat medical conditions, and increase the reach of healthcare providers to remote areas.
The tailored solutions offered by Kallo complement existing infrastructure, workflows, and processes, increasing both uptime and productivity. The company’s suite of products complies with international, national, and regional standards, and its stringent quality control ensures repeatable, process-driven delivery for maximum performance.
Kallo’s executives and directors bring rich and diverse industry knowledge. Collectively, the management team reflects the strength of the company’s global network and the diversity of its global culture. The team’s entrepreneurship, passion, experience, and knowledge of healthcare enables Kallo to continually deliver higher standards.
Neutra Corp. (NTRR)
Neutra Corp. is a multi-faceted early-stage research and development company that’s bringing modern healthy living solutions to various multi-billion dollar markets. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture—one where consumers are demanding access to products that promote health and stave off potential health dangers.
The company’s current product portfolio includes a variety of offerings within the rapidly growing nutraceuticals, food and drug, and environmental sectors. Neutra has established several joint-venture partnerships, and through a joint venture with Air to Surface Solutions, LLC, the company is in developing a new technology to address the problems of plant contaminations and dangerous staph infections (MRSA) among athletes. Neutra is focused on the commercialization of newer, more effective products that eliminate bacteria from the air and tangible surfaces and aims to capitalize on a worldwide boom in these products.
Scientists recently found that topical cannabinoid-based preparations can be effective against MRSA, the deadly antibiotic-resistant flesh-eating disease. Neutra is exploring the potential to bring these therapeutic remedies to the global market. Medicinal cannabis is used to provide relief for patients suffering from the side-effects of chemotherapy and other invasive treatments, as well as pain relief from a range of neurological diseases such as multiple sclerosis.
Neutra has established a partnership with the exclusive Canadian distributor of Purteq. This revolutionary technology is designed to control indoor air contamination, the subsequent microorganism infestations and allergens, and to prevent the spread of diseases such as influenza. Purteq is a patent-pending green technology that works similar to photosynthesis. The product utilizes UV-blue light and water in the air and converts them into microscopic amounts of water, carbon dioxide, and harmless bi-products. This proven technology controls air quality in businesses and homes and opens the path for Neutra to participate in the burgeoning North American air purification market, which is forecast to reach $4.8 billion by 2017.
The global nutraceuticals product market is projected grow to $204.8 billion by 2017. Neutra is positioned for this market with its Pure Plus all-natural weight-loss supplement. The product is based on the company’s groundbreaking Bio-Energy infusion compound, designed to enhance the effects of a supplement’s ingredients to help supercharge the body’s natural weight-loss process and work more quickly and effectively than competing products.
Neutra’s mission is to deliver the highest quality consumer healthy living products while continuing to seek breakthrough advances in the healthy living market.
Pan Global Corp. (PGLO)
Pan Global Corp. is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth.
Puget Technologies (PUGE)
Puget Technologies is an innovator of 3D printing technologies and products. The company aims to advance its portfolio and become a recognized leader in the lucrative 3D printing market, which is expected to top $8.4 billion in 2020 with a compound annual growth rate of 23%. 3D printing will revolutionize the way consumer goods are made, and Puget Technologies’ aims to capture its market share of the billowing industry by offering leading-edge, consumer-oriented personal 3D printers, 3D image library availability, and licensed image access.
PrintSnaptic is the company’s software solution and user interface that functions as a design tool to enable the user to easily view and edit images of their product on a computer screen, and then connect to any P3D printer to cut the design. PrintSnaptic will feature the largest 3D source file image database, offering digital rights (i.e. copyright); licensed source files for sale; and user-generated source files for sale.
Puget Technologies’ intellectual property includes SnapSearch, a smartphone app that allows the user to take a picture of an image or scan a UPC symbol to search the PrintSnaptic database of 3D source files to create their own product. The company’s Eco-Fil technology includes a proprietary series of consumable filaments for 3D printers that are clean and more environmentally friendly due to the ability to recycle not only unused or partially used cartridges, but completed 3D projects.
Initiatives are spearheaded by a management team with a proven ability to identify trends, generate new products, produce and develop branding for individual products and product lines, and create innovative sales and distribution strategies worldwide, while maintaining the highest standards. The leadership and management team of Puget Technologies is committed to progression of technology and the best interests of its shareholders.